COVID-19 and Child

Abstract

The novel Coronavirus disease 2019 is originated from severe acute respiratory syndrome coronavirus 2 (COVID-19), which is a member of Betacoronavirus. COVID-19 was detected in large group of patients with acute respiratory failure syndrome in Wuhan, China in December 2019. Coronaviruses were isolated from several hosts including mice, chickens, pigs, dogs, cats, bats, rabbits, horses, cattle and humans. The virus may be transmitted by droplet, aerosolation and contact. Whether the transition of virus from mother to baby during pregnancy is uncertain. Common symptoms of infection are fever, cough, and dyspnea. The severity of disease could differentiate from asymptomatic to severe acute respiratory syndrome. The patients indicated for hospitalization are under one year old infants or children with chronic lung disease (asthma), cardiovascular disease and immunosuppressed children. Poor prognostic criteria are determined as; lymphocyte count is <800 / µl or CRP> 40 mg / l or ferritin> 500ng / ml or D-Dimer> 1000 ng / ml. Computed tomography may be helpful for making diagnosis and differential diagnosis. Typical radiological signs of COVID-19 pneumonia are interstitial inflammation, widespread consolidation, unilateral or bilateral patchy involvement, ground-glass opacities. There may be peripheral and subpleural involvement. Blocking the virus is one of the most restrictive points of treatment due to its large RNA, several repetitive parts, and usage of different receptors in different types.

Keywords

• COVID-19,SARS-CoV-2,child

COVID-19 ve Çocuk

Abstract

Yeni Koronavirüs 2019 hastalığı Betakoronavirus ailesinden şiddetli akut solunum yetmezliği koronavirus 2 (COVID-19) virüsünden kaynaklanmaktadır. COVID-19 hastalığı Çin, Wuhan’da büyük bir grup hastada görülen akut solunum yolu yetmezliği sendromu ile belirlenmiştir. Koronovirüsler fareleri, tavukları, hindileri, domuzları, köpekleri, kedileri, yarasaları, tavşanları, atları, sığırları ve insanları içine alan geniş birçok konak grubundan izole edilmiştir. İnsanlardaki CoV’un ana bulaş şekilleri damlacık enfeksiyonu, aerosolizasyon ve enfeksiyon nakletme özelliği olan eşyalarladır. Virüsün gebelikte anneden bebeğe geçip geçmediği belirsizdir. Enfeksiyonun yaygın belirtileri solunum semptomları, ateş, öksürük ve dispnedir. İnsanlarda koronavirüs enfeksiyonu asemptomatik olabileceği gibi ağır akut solunum sendromuna kadar değişkenlik gösterebilmektedir. Hastanede yatış gereken hastaların çoğunlukla bir yaş altı süt çocuğu olduğu ve eşlik eden hastalıklar olarak da çoğunlukla kronik akciğer hastalığı (astım), kardiyovasküler hastalık ve immunsüprese çocuklar olduğu tespit edilmiştir. Belirlenen kötü prognostik kriterler; lenfosit sayısı <800/ µl veya CRP>40 mg/l veya ferritin >500ng/ml veya D-Dimer>1000 ng/ml’dır. Bilgisayarlı Tomografi tanı koymada veya ayırıcı tanıda yardımcı olabilir. COVID-19 pnömonisinin tipik radyolojik bulguları interstisyel inflamasyon, yaygın konsolidasyon, tek taraflı veya bilateral yamasal tutulum ve buzlu cam opasiteleridir. Periferal ve subplevral tutulum olabilir. Büyük bir RNA’ya sahip olması, tekrarlayan kısımları fazla olması ve farklı türlerde farklı reseptörleri kullanması nedeni ile virüsü bloke etmek tedavinin en kısıtlayıcı noktalarındandır.

Keywords

• COVID-19,SARS-CoV-2,çocuk

References

1. 1. Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
2. 2. WHO. Coronavirus disease 2019 (COVID19): situation report erişim: https://who.sprinklr. com/ 12.Nisan 2020
3. 3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Preventionexternal icon. JAMA. Published online: February 24, 2020. DOI:10.1001/ jama.2020.2648.
4. 4. CDC  COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) -  United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep.  2020;69(12):343-6. doi: 10.15585/mmwr.mm6912e2.
5. 5. Poutanen S, Low B, Henry S, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348:1995-2005.
6. 6. World Health Organization. 21 April 2004 Summary of probable SASR cases with onset of illness from Nov 2002 to July 2003. erişim: http:// www.who.int/csr/sars/country/en/ Şubat 2013.
7. 7. Suudi Arabistan’da orta doğu solunum sendromu koronavirüsü (MERS-COV) https://www. seyahatsagligi.gov.tr/Site/HaberDetayi/2322 erişim:12.04.2020
8. 8. Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia Emergencies preparedness, response Disease Outbreak News (DONs) Erişim: https://www. who.int/csr/don/08-april-2020-mers-saudiarabia/en/ erişim:12.04.2020

9. 9. Vallet S, Gagneur P, Talbot M, et al. Detection of human coronavirus 229E in nasal specimens in large scale studies using an RT-PCR. Mol Cell Probes 2004;18:75-80.
10. 10. Vabret T, Mourez S, Gouren J, et al. An outbreak of coronavirus OC43 respiratory infection in Normandy. Clin Infect Dis 2003;36:985-9.
11. 11. Kampf, G., Todt, D., Pfaender, S.,Steinmann, E. (2020). Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. Journal of Hospital Infection. 2020;104(3):24651 doi:10.1016/j.jhin.2020.01.022 
12. 12. Hon L, Leung W, Cheng P, et al. Clinical presentation and outcome of SARS in children Lancet 2004;361:1701-3.
13. 13. Yuanyuan Dong, Xi Mo, Yabin Hu, Xin Qi, Fan Jiang, Zhongyi Jiang, Shilu Tong. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6):e20200702
14. 14. CDC COVID-19 Response Team, Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020, Morbidity and Mortality Weekly Report Weekly 2020;69(14):422-6
15. 15. Dong Y, Mo X, HuY, Qi X, Jiang F, Jiang Z, et al. Epidemiologicalcharacteristicsof 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020. 2020 Mar 16. pii: e20200702. doi: 10.1542/peds.2020-0702. [Epub ahead of print]
16. 16. Lu Q, Shi Y. Coronavirus disease (COVID-19) and neonate: What neonatologist need to know. J Med Virol. 2020;1-4 doi: 10.1002/jmv.25740.
17. 17. Siddiqi HK., Mehra MR. COVID-19 Illness in native and immunosuppressed states: a clinical-therapeutic staging proposal, journal of heart and lung transplantation (2020), PMCID: PMC7118652 [Epub ahead of print] doi: https://doi.org/10.1016/j.healun.2020.03.012
18. 18. Henry BM, Lippia G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med. 2020 Mar 16. pii: /j/cclm.ahead-of-print/cclm-2020-0272/ cclm-2020-0272.xml. doi: 10.1515/cclm-20200272. [Epub ahead of print]
19. 19. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 in- fection: Different points from adults [published online ahead of print, Pediatric Pulmonology 2020;55:1169–74 . DOI: 10.1002/ppul.24718 20. T.C. Sağlık Bakanlığı COVID-19(sars-cov-2 enfeksiyonu) rehberi. 12 Nisan 2020, Ankara
20. 21. Wu J., Li W, Shi X, Chen Z, Jiang B. et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020 doi: 10.1111/joim.13063. [Epub ahead of print]
21. 22. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. Engl J Med. 2020. doi: 10.1056/ NEJMoa2001282. [Epub ahead of print]
22. 23. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther.  2020;14(1):58-60. doi: 10.5582/ ddt.2020.01012.
23. 24. Zhou D., Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob 2020 Mar 20. Chemother doi:10.1093/jac/dkaa114
24. 25. Gautret P ., Lagier JC., Parola P., Hoang VT. et.al Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. . Int J Antimicrob Agents.  2020 Mar 20:105949. doi: 10.1016/j. ijantimicag.2020.105949. [Epub ahead of print]
25. 26. Zhou Y, Yang Y, Huang J, Jiang S, Du L. Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. Viruses. 2019 Jan 14;11(1).